12. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, et al. (2001) Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413: 131–138. 13. Malik S, Roeder RG (2005) Dynamic regulation of pol II transcription by the mammalian Mediator complex. Trends Biochem Sci 30: 256–263. 14. Malik S, Roeder RG (2000) Transcriptional regulation through Mediator-like coactivators in yeast and metazoan cells. Trends Biochem Sci 25: 277–283. 15. Fondell JD, Ge H, Roeder RG (1996) Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci U S A 93: 8329–8333. 16. Belakavadi M, Fondell JD (2006) Role of the mediator complex in nuclear hormone receptor signaling. Rev Physiol Biochem Pharmacol 156: 23–43. 17. Casamassimi A, Napoli C (2007) Mediator complexes and eukaryotic transcription regulation: an overview. Biochimie 89: 1439–1446. 18. Rha GB, Wu G, Shoelson SE, Chi YI (2009) Multiple binding modes between HNF4alpha and the LXXLL motifs of PGC-1alpha lead to full activation. J Biol Chem. 19. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, et al. (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127: 126–132. 20. Lewis BA, Reinberg D (2003) The mediator coactivator complex: functional and physical roles in transcriptional regulation. Journal of cell science 116: 3667– 3675. 21. Lee HK, Park UH, Kim EJ, Um SJ (2007) MED25 is distinct from TRAP220/ MED1 in cooperating with CBP for retinoid receptor activation. EMBO J 26: 3545–3557. 22. Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, et al. (1993) Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose- stimulated insulin secretion similar to those of normal islets. Diabetologia 36: 1139–1145. 23. Rochette-Egly C (2005) Dynamic combinatorial networks in nuclear receptor- mediated transcription. J Biol Chem 280: 32565–32568. 24. Perissi V, Rosenfeld MG (2005) Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6: 542–554. 25. Xu J, Li Q (2003) Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17: 1681–1692. 26. Maeda Y, Rachez C, Hawel L, 3rd, Byus CV, Freedman LP, et al. (2002) Polyamines modulate the interaction between nuclear receptors and vitamin D receptor-interacting protein 205. Mol Endocrinol 16: 1502–1510. 27. Conaway RC, Conaway JW (2011) Function and regulation of the Mediator complex. Current opinion in genetics & development 21: 225–230. 28. Owen K, Hattersley AT (2001) Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best practice & research Clinical endocrinology & metabolism 15: 309–323. 29. Shih DQ, Stoffel M (2002) Molecular etiologies of MODY and other early-onset forms of diabetes. Curr Diab Rep 2: 125–134. 30. Wang H, Maechler P, Antinozzi PA, Hagenfeldt KA, Wollheim CB (2000) Hepatocyte Nuclear Factor 4alpha regulates the expression of pancreatic beta - cell genes implicated in glucose metabolism and nutrient-induced insulin secretion. J Biol Chem 275: 35953–35959. 31. Stoffel M, Duncan SA (1997) The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 94: 13209–13214. 32. Haider S, Antcliff JF, Proks P, Sansom MS, Ashcroft FM (2005) Focus on Kir6.2: a key component of the ATP-sensitive potassium channel. Journal of molecular and cellular cardiology 38: 927–936. 33. Ashcroft FM (2005) ATP-sensitive potassium channelopathies: focus on insulin secretion. The Journal of clinical investigation 115: 2047–2058. HNF4a-MED25 Interactions in Beta-Cells 34. Malik S, Wallberg AE, Kang YK, Roeder RG (2002) TRAP/SMCC/mediator- dependent transcriptional activation from DNA and chromatin templates by orphan nuclear receptor hepatocyte nuclear factor 4. Mol Cell Biol 22: 5626– 5637. 35. Chen W, Rogatsky I, Garabedian MJ (2006) MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Molecular endocrinology 20: 560–572. 36. Ding N, Tomomori-Sato C, Sato S, Conaway RC, Conaway JW, et al. (2009) MED19 and MED26 are synergistic functional targets of the RE1 silencing transcription factor in epigenetic silencing of neuronal gene expression. J Biol Chem 284: 2648–2656. 37. Kim TW, Kwon YJ, Kim JM, Song YH, Kim SN, et al. (2004) MED16 and MED23 of Mediator are coactivators of lipopolysaccharide- and heat-shock- induced transcriptional activators. Proceedings of the National Academy of Sciences of the United States of America 101: 12153–12158. 38. Rha GB, Wu G, Chi YI (2011) Probing the effect of MODY mutations near the coactivator binding pocket of HNF4alpha. Bioscience reports 31: 411–419. 39. Mita Y, Dodo K, Noguchi-Yachide T, Miyachi H, Makishima M, et al. (2010) LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators. Bioorganic & medicinal chemistry letters 20: 1712–1717. 40. Sun A, Moore TW, Gunther JR, Kim MS, Rhoden E, et al. (2011) Discovering small-molecule estrogen receptor alpha/coactivator binding inhibitors: high- throughput screening, ligand development, and models for enhanced potency. ChemMedChem 6: 654–666. 41. Rana R, Surapureddi S, Kam W, Ferguson S, Goldstein JA (2011) Med25 is required for RNA polymerase II recruitment to specific promoters, thus regulating xenobiotic and lipid metabolism in human liver. Molecular and cellular biology 31: 466–481. 42. Sladek FM, Ruse MD Jr, Nepomuceno L, Huang SM, Stallcup MR (1999) Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1. Mol Cell Biol 19: 6509–6522. 43. Duda K, Chi Y-I, Shoelson SE (2004) Structural Basis for HNF-4alpha Activation by Ligand and Coactivator Binding. J Biol Chem 279: 23311–23316. 44. Borggrefe T, Yue X (2011) Interactions between subunits of the Mediator complex with gene-specific transcription factors. Seminars in cell & develop- mental biology 22: 759–768. 45. Lu P, Rha GB, Melikishvili M, Wu G, Adkins BC, et al. (2008) Structural basis of natural promoter recognition by a unique nuclear receptor, HNF4alpha. Diabetes gene product. J Biol Chem 283: 33685–33697. 46. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993–996. 47. Mukherjee S, Mani S (2010) Orphan nuclear receptors as targets for drug development. Pharm Res 27: 1439–1468. 48. Higgins LS, Depaoli AM (2010) Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 91: 267S–272S. 49. Shanle EK, Xu W (2010) Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev 62: 1265–1276. 50. Rosano C, Stec-Martyna E, Lappano R, Maggiolini M (2011) Structure-based approach for the discovery of novel selective estrogen receptor modulators. Current medicinal chemistry 18: 1188–1194. 51. Berg T (2008) Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Devel 11: 666–674. 52. Galande AK, Bramlett KS, Trent JO, Burris TP, Wittliff JL, et al. (2005) Potent inhibitors of LXXLL-based protein-protein interactions. Chembiochem 6: 1991–1998. 53. Hsia EY, Goodson ML, Zou JX, Privalsky ML, Chen HW (2010) Nuclear receptor coregulators as a new paradigm for therapeutic targeting. Adv Drug Deliv Rev 62: 1227–1237. PLOS ONE | www.plosone.org 10 August 2012 | Volume 7 | Issue 8 | e44007